REPORT ID 5470

Global Meningioma Drug Sales Market Report 2017

Publish Date
21-Dec-17
Pages
114
Format
Electronic (PDF)

In this report, the global Meningioma Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Meningioma Drug for these regions, from 2012 to 2022 (forecast), covering
    United States
    China
    Europe
    Japan
    Southeast Asia
    India

Global Meningioma Drug market competition by top manufacturers/players, with Meningioma Drug sales volume, Price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Arno Therapeutics Inc
    AstraZeneca Plc
    Boehringer Ingelheim GmbH
    Eli Lilly and Co
    Genentech Inc
    GlaxoSmithKline Plc
    Merck & Co Inc
    Merck KGaA
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Pharma Mar SA
    Progenics Pharmaceuticals Inc
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Abemaciclib
    Afatinib Dimaleate
    AR-42
    Avelumab
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Meningioma Drug Sales Market Report 2017
1 Meningioma Drug Market Overview
    1.1 Product Overview and Scope of Meningioma Drug
    1.2 Classification of Meningioma Drug by Product Category
        1.2.1 Global Meningioma Drug Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 Global Meningioma Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Abemaciclib
        1.2.4 Afatinib Dimaleate
        1.2.5 AR-42
        1.2.6 Avelumab
        1.2.7 Others
    1.3 Global Meningioma Drug Market by Application/End Users
        1.3.1 Global Meningioma Drug Sales (Volume) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Meningioma Drug Market by Region
        1.4.1 Global Meningioma Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 United States Meningioma Drug Status and Prospect (2012-2022)
        1.4.3 China Meningioma Drug Status and Prospect (2012-2022)
        1.4.4 Europe Meningioma Drug Status and Prospect (2012-2022)
        1.4.5 Japan Meningioma Drug Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Meningioma Drug Status and Prospect (2012-2022)
        1.4.7 India Meningioma Drug Status and Prospect (2012-2022)
    1.5 Global Market Size (Value and Volume) of Meningioma Drug (2012-2022)
        1.5.1 Global Meningioma Drug Sales and Growth Rate (2012-2022)
        1.5.2 Global Meningioma Drug Revenue and Growth Rate (2012-2022)

2 Global Meningioma Drug Competition by Players/Suppliers, Type and Application
     2.1 Global Meningioma Drug Market Competition by Players/Suppliers
        2.1.1 Global Meningioma Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Global Meningioma Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Global Meningioma Drug (Volume and Value) by Type
        2.2.1 Global Meningioma Drug Sales and Market Share by Type (2012-2017)
        2.2.2 Global Meningioma Drug Revenue and Market Share by Type (2012-2017)
    2.3 Global Meningioma Drug (Volume and Value) by Region
        2.3.1 Global Meningioma Drug Sales and Market Share by Region (2012-2017)
        2.3.2 Global Meningioma Drug Revenue and Market Share by Region (2012-2017)
    2.4 Global Meningioma Drug (Volume) by Application

3 United States Meningioma Drug (Volume, Value and Sales Price)
    3.1 United States Meningioma Drug Sales and Value (2012-2017)
        3.1.1 United States Meningioma Drug Sales and Growth Rate (2012-2017)
        3.1.2 United States Meningioma Drug Revenue and Growth Rate (2012-2017)
        3.1.3 United States Meningioma Drug Sales Price Trend (2012-2017)
    3.2 United States Meningioma Drug Sales Volume and Market Share by Players
    3.3 United States Meningioma Drug Sales Volume and Market Share by Type
    3.4 United States Meningioma Drug Sales Volume and Market Share by Application

4 China Meningioma Drug (Volume, Value and Sales Price)
    4.1 China Meningioma Drug Sales and Value (2012-2017)
        4.1.1 China Meningioma Drug Sales and Growth Rate (2012-2017)
        4.1.2 China Meningioma Drug Revenue and Growth Rate (2012-2017)
        4.1.3 China Meningioma Drug Sales Price Trend (2012-2017)
    4.2 China Meningioma Drug Sales Volume and Market Share by Players
    4.3 China Meningioma Drug Sales Volume and Market Share by Type
    4.4 China Meningioma Drug Sales Volume and Market Share by Application

5 Europe Meningioma Drug (Volume, Value and Sales Price)
    5.1 Europe Meningioma Drug Sales and Value (2012-2017)
        5.1.1 Europe Meningioma Drug Sales and Growth Rate (2012-2017)
        5.1.2 Europe Meningioma Drug Revenue and Growth Rate (2012-2017)
        5.1.3 Europe Meningioma Drug Sales Price Trend (2012-2017)
    5.2 Europe Meningioma Drug Sales Volume and Market Share by Players
    5.3 Europe Meningioma Drug Sales Volume and Market Share by Type
    5.4 Europe Meningioma Drug Sales Volume and Market Share by Application

6 Japan Meningioma Drug (Volume, Value and Sales Price)
    6.1 Japan Meningioma Drug Sales and Value (2012-2017)
        6.1.1 Japan Meningioma Drug Sales and Growth Rate (2012-2017)
        6.1.2 Japan Meningioma Drug Revenue and Growth Rate (2012-2017)
        6.1.3 Japan Meningioma Drug Sales Price Trend (2012-2017)
    6.2 Japan Meningioma Drug Sales Volume and Market Share by Players
    6.3 Japan Meningioma Drug Sales Volume and Market Share by Type
    6.4 Japan Meningioma Drug Sales Volume and Market Share by Application

7 Southeast Asia Meningioma Drug (Volume, Value and Sales Price)
    7.1 Southeast Asia Meningioma Drug Sales and Value (2012-2017)
        7.1.1 Southeast Asia Meningioma Drug Sales and Growth Rate (2012-2017)
        7.1.2 Southeast Asia Meningioma Drug Revenue and Growth Rate (2012-2017)
        7.1.3 Southeast Asia Meningioma Drug Sales Price Trend (2012-2017)
    7.2 Southeast Asia Meningioma Drug Sales Volume and Market Share by Players
    7.3 Southeast Asia Meningioma Drug Sales Volume and Market Share by Type
    7.4 Southeast Asia Meningioma Drug Sales Volume and Market Share by Application

8 India Meningioma Drug (Volume, Value and Sales Price)
    8.1 India Meningioma Drug Sales and Value (2012-2017)
        8.1.1 India Meningioma Drug Sales and Growth Rate (2012-2017)
        8.1.2 India Meningioma Drug Revenue and Growth Rate (2012-2017)
        8.1.3 India Meningioma Drug Sales Price Trend (2012-2017)
    8.2 India Meningioma Drug Sales Volume and Market Share by Players
    8.3 India Meningioma Drug Sales Volume and Market Share by Type
    8.4 India Meningioma Drug Sales Volume and Market Share by Application

9 Global Meningioma Drug Players/Suppliers Profiles and Sales Data
    9.1 Arno Therapeutics Inc
        9.1.1 Company Basic Information, Manufacturing Base and Competitors
        9.1.2 Meningioma Drug Product Category, Application and Specification
            9.1.2.1 Product A
            9.1.2.2 Product B
        9.1.3 Arno Therapeutics Inc Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.1.4 Main Business/Business Overview
    9.2 AstraZeneca Plc
        9.2.1 Company Basic Information, Manufacturing Base and Competitors
        9.2.2 Meningioma Drug Product Category, Application and Specification
            9.2.2.1 Product A
            9.2.2.2 Product B
        9.2.3 AstraZeneca Plc Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.2.4 Main Business/Business Overview
    9.3 Boehringer Ingelheim GmbH
        9.3.1 Company Basic Information, Manufacturing Base and Competitors
        9.3.2 Meningioma Drug Product Category, Application and Specification
            9.3.2.1 Product A
            9.3.2.2 Product B
        9.3.3 Boehringer Ingelheim GmbH Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.3.4 Main Business/Business Overview
    9.4 Eli Lilly and Co
        9.4.1 Company Basic Information, Manufacturing Base and Competitors
        9.4.2 Meningioma Drug Product Category, Application and Specification
            9.4.2.1 Product A
            9.4.2.2 Product B
        9.4.3 Eli Lilly and Co Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.4.4 Main Business/Business Overview
    9.5 Genentech Inc
        9.5.1 Company Basic Information, Manufacturing Base and Competitors
        9.5.2 Meningioma Drug Product Category, Application and Specification
            9.5.2.1 Product A
            9.5.2.2 Product B
        9.5.3 Genentech Inc Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.5.4 Main Business/Business Overview
    9.6 GlaxoSmithKline Plc
        9.6.1 Company Basic Information, Manufacturing Base and Competitors
        9.6.2 Meningioma Drug Product Category, Application and Specification
            9.6.2.1 Product A
            9.6.2.2 Product B
        9.6.3 GlaxoSmithKline Plc Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.6.4 Main Business/Business Overview
    9.7 Merck & Co Inc
        9.7.1 Company Basic Information, Manufacturing Base and Competitors
        9.7.2 Meningioma Drug Product Category, Application and Specification
            9.7.2.1 Product A
            9.7.2.2 Product B
        9.7.3 Merck & Co Inc Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.7.4 Main Business/Business Overview
    9.8 Merck KGaA
        9.8.1 Company Basic Information, Manufacturing Base and Competitors
        9.8.2 Meningioma Drug Product Category, Application and Specification
            9.8.2.1 Product A
            9.8.2.2 Product B
        9.8.3 Merck KGaA Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.8.4 Main Business/Business Overview
    9.9 Novartis AG
        9.9.1 Company Basic Information, Manufacturing Base and Competitors
        9.9.2 Meningioma Drug Product Category, Application and Specification
            9.9.2.1 Product A
            9.9.2.2 Product B
        9.9.3 Novartis AG Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.9.4 Main Business/Business Overview
    9.10 Ono Pharmaceutical Co Ltd
        9.10.1 Company Basic Information, Manufacturing Base and Competitors
        9.10.2 Meningioma Drug Product Category, Application and Specification
            9.10.2.1 Product A
            9.10.2.2 Product B
        9.10.3 Ono Pharmaceutical Co Ltd Meningioma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.10.4 Main Business/Business Overview
    9.11 Pharma Mar SA
    9.12 Progenics Pharmaceuticals Inc

10 Meningioma Drug Maufacturing Cost Analysis
    10.1 Meningioma Drug Key Raw Materials Analysis
        10.1.1 Key Raw Materials
        10.1.2 Price Trend of Key Raw Materials
        10.1.3 Key Suppliers of Raw Materials
        10.1.4 Market Concentration Rate of Raw Materials
    10.2 Proportion of Manufacturing Cost Structure
        10.2.1 Raw Materials
        10.2.2 Labor Cost
        10.2.3 Manufacturing Process Analysis of Meningioma Drug
    10.3 Manufacturing Process Analysis of Meningioma Drug

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
    11.1 Meningioma Drug Industrial Chain Analysis
    11.2 Upstream Raw Materials Sourcing
    11.3 Raw Materials Sources of Meningioma Drug Major Manufacturers in 2016
    11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
    12.1 Marketing Channel
        12.1.1 Direct Marketing
        12.1.2 Indirect Marketing
        12.1.3 Marketing Channel Development Trend
    12.2 Market Positioning
        12.2.1 Pricing Strategy
        12.2.2 Brand Strategy
        12.2.3 Target Client
    12.3 Distributors/Traders List

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes Threat
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs/Customer Preference Change
    13.3 Economic/Political Environmental Change

14 Global Meningioma Drug Market Forecast (2017-2022)
    14.1 Global Meningioma Drug Sales Volume, Revenue and Price Forecast (2017-2022)
       14.1.1 Global Meningioma Drug Sales Volume and Growth Rate Forecast (2017-2022)
       14.1.2 Global Meningioma Drug Revenue and Growth Rate Forecast (2017-2022)
       14.1.3 Global Meningioma Drug Price and Trend Forecast (2017-2022)
    14.2 Global Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
       14.2.1 Global Meningioma Drug Sales Volume and Growth Rate Forecast by Regions (2017-2022)
       14.2.2 Global Meningioma Drug Revenue and Growth Rate Forecast by Regions (2017-2022)
       14.2.3 United States Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.4 China Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.5 Europe Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.6 Japan Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.7 Southeast Asia Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.8 India Meningioma Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
    14.3 Global Meningioma Drug Sales Volume, Revenue and Price Forecast by Type (2017-2022)
       14.3.1 Global Meningioma Drug Sales Forecast by Type (2017-2022)
       14.3.2 Global Meningioma Drug Revenue Forecast by Type (2017-2022)
       14.3.3 Global Meningioma Drug Price Forecast by Type (2017-2022)
    14.4 Global Meningioma Drug Sales Volume Forecast by Application (2017-2022)

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology/Research Approach
        16.1.1 Research Programs/Design
        16.1.2 Market Size Estimation
        16.1.3 Market Breakdown and Data Triangulation
    16.2 Data Source
        16.2.1 Secondary Sources
        16.2.2 Primary Sources
    16.3 Disclaimer